The US Specialty Pharmaceutical Market Report: 2013 Edition - New Report by Koncept Analytics

7/22/2019 The US Specialty Pharmaceutical Market Report: 2013 Edition - New Report by Koncept Analytics

http://slidepdf.com/reader/full/the-us-specialty-pharmaceutical-market-report-2013-edition-new-report-by 1/10

The US Specialty Pharmaceutical Market-----------------------------------------------------

2013

View Report Details

http://www.konceptanalytics.com/reportDetail.aspx?reportID=517




Executive Summary

Specialty pharmaceuticals are defined as a new, rapidly growing drugs and biologics that are manufactured as a result of continuedadvancements in drug technology and design. These pharmaceuticals are specialized, high cost products which can be difficult toadminister and may require patient monitoring. Specialty pharmaceuticals are utilized as complex therapies for complex chronicdiseases such as cancer, hemophilia, multiple sclerosis, HIV, hepatitis C, apart from others. Some of the specialized drugs that areused for treating such conditions meet all the three H’s: High Cost, High Complexity and High Touch and they require extensiveeducation for safe and cost-effective use. The specialty pharmaceuticals are mostly injectable or infused medicines but may alsoencompass oral medications.

Specialty pharmacy is a special class of provider that are primarily responsible for distributing and dispensing the pharmaceutical asspecialty pharmaceutical require specialized shipping and temperature-controlled storing and handling. Specialty pharmacy can beowned by stand-alone companies or large pharmacy chains. However, some drug wholesalers are also capable of shipping thespecialty pharmaceuticals. There exists a substantial incentive for companies to research and develop products that address the

unmet need of the patients as the specialty pharmaceutical market has the ability to sustain the high cost of these products therebyadditionally offering a business perspective for the biopharmaceutical companies.

The key factors driving growth of the US specialty pharmaceutical industry include accelerating US aging population, amelioratingeconomic condition, increased life expectancy, and increasing healthcare expenditure. Some of the noteworthy trends anddevelopments of this industry include rising Medicare enrollment, novel specialty products in pipeline, conversion of patents to genericdrugs, increased spending on specialty drugs and ongoing merger & acquisition activities. However, the growth of the industry is beinghindered by lack of rigorous clinical trials, sluggish pace of innovation and inappropriate use of therapeutic drugs.

The specialty pharmaceutical market witnesses fierce competition with numerous top notch players; such as such as Amgen, Pfizer, EliLilly, Roche, Johnson & Johnson and Novo Nordisk; operating in the market place along with small budding players. The fierce

competition prevailing in the US specialty pharmaceutical industry has been studied on a number of parameters such as competingdrugs, mail pharmacies and distributors. The company profiles of leading aforementioned players in the market are also presented inthe report.

By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have predicted the future growth ofthe industry. We employed various significant variables that have an impact on this industry and created regression models with SPSSBase to determine the future direction of the industry. Before deploying the regression model, the relationship between severalindependent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables andtests.

View Report Details





Special pharmaceutical category can be classified into one of the following types: Orphan Drugs,Biotechnology Products, Blood Products and products defined by complex medical condition.

• The global pharmaceutical market has been consistently growingsince almost a decade. Over the past couple of years, a hugesuccess is being noted in the phase III trials of therapeutic drugs.Marking an incline of ….%, the global pharmaceutical marketreached US$.… billion at the end of 2012, compared to US$....

billion during the prior year.

• North America held a healthy share of ….% of the globalpharmaceutical market at the end of 2012. Europe was the secondlargest market with ….% share, followed by combined share of….% of Asia, Africa, India and Australia.

•The pharmaceutical market in the US inclined by ….%, reachingUS$.... billion in 2012, compared to US$.... billion during theprevious year. Furthermore, the growth of the pharmaceuticalindustry in the US was noted at a CAGR of …..% during the periodspanning 2008 to 2012.

The US Pharmaceutical Market (2008-2012)Regional Percentage Share in Global Pharmaceutical Market (2012)

Global Pharmaceutical Market (2003-2013E)

NA Europe As, Af, In, Aus Japan Latin America Others

U S $ B i l l i o n

U S $

B i l

l i o n



Specialty pharmaceuticals are specialized, high cost products which can be difficult to administer andmay require patient monitoring and are used for treating complex chronic conditions.

• The traditional pharmaceutical sales in the US consistentlyincreased till 2011. However, the overall sales of the traditionalpharmaceutical were noted at US$..... billion in 2012, down by….%, compared to US$..... billion in 2011.

• The sales of the specialty pharmaceuticals increased to US$.....billion in 2012. This represented a remarkable incline of ….%,compared to US$.... billion during the prior year. Further, thegrowth of the aforementioned segment was recorded at animpressive CAGR of …..%, during the period spanning 2008 to2012.

• Growth of specialty drug is viewed as one of the major trend ofthe industry. In the category of specialty drugs, mail delivery andretail dispensing channels held an equal share of ….% each during2012 immediately followed by physician office with ….% share. The

other dispensing channels include outpatients, home health andinpatient with shares of ….%, …% and ….%, respectively.

Specialty Market Share by Dispensing Channels (2012)The US Specialty Pharmaceutical Market (2008-2012)

The US Traditional Pharmaceutical Market (2008-2012)

U S $ B i l l i o n

Mail Delivery Retail Physician Office

Outpatient Home Health Inpatient

U S $ B i l l i o n



The key factors driving growth of the US specialty pharmaceutical industry include accelerating US agingpopulation, increased life expectancy, and increasing healthcare expenditure.

• In 2012, oncology represented highest sales of US$.... billionimmediately followed by rheumatoid arthritis with sales equivalentto US$.... billion. In terms of percentage share, oncology accountedfor a healthy ….% of the total sales in 2012. Rheumatoid arthritiswas the second largest contributor with moderate ….% share

followed by …% share of HIV/AIDS therapeutic area.

• During 2012, AmerisourceBergen commanded a staggering shareof ….% while McKesson accounted for ….% of the same. MetroMedical and CuraScript held respective shares of ….% and ….%.

• The leading two companies; Express Script and CVS Caremark;accounting for combined share of …..% of the total market in termsof specialty mail pharmacy market during 2012. Furthermore,Express Script, CVS Caremark and Walgreen represented sharesof …..%, …..% and ….%, respectively.

Specialty Mail Pharmacy Market Share (2012)Specialty Distributors Market Share (2012)

Share of Constituents of Specialty Pharmaceutical Market (2012)

ABC McKesson Metro Medical CuraScript Others

Oncology (incl. oral solids) Rheumatoid arthritis/Crohn's

HIV/AIDS (including oral solids) Multiple sclerosis

Renal IVIG/ Hemophilia

Express Script CVS Caremark

Walgreens Diplomat Specialty Pharmacy

Omnicare Retail and Other Specialty Pharmacies



Specialty pharmacy services are divided sub divided into four types namely; Packaging and Delivery,Reimbursement, Inbound and Outbound Clinical Support and Compliance and Persistence Program.

Accounting for ….% share, Humira was the leading drug in the US marketplace in 2012, immediately followed by Abilify with ….% share.Further, Seretide, Lantus and Enbrel accounted for equal share of …..%, each, of the sales of leading 10 drugs. Other drugs which dominatedthe marketplace during the cited period include Cymbalta, Remicade, Rituxan, Neulasta and Crestor.

The US specialty pharmaceutical market is forecasted to increase by …..% to reach US$.... billion by the end of 2013, compared to US$....

billion in the previous year. Further, the market is forecasted to reach US$..... billion by the end of 2017 thus registering growth at a remarkableCAGR of …..% during the period spanning 2012 to 2017.

The specialty pharmaceutical market witnesses’ fierce competition with numerous top notch players operating in the marketplace along withsmall budding players steeply inclined towards discovering and devising novel therapeutic molecules which address the unmet needs of theconcerned disease area. This represents the evolution of specialty pharmaceutical industry over the past couple of years. Specialty distributionrepresents lucrative growth opportunity for the distributors as it is one of the largest and rapidly growing segments. Specialty distribution is adensely consolidated industry with handful players dominating the marketplace as compared to the traditional drug distribution channels.Specialty margins tend to be a bit higher as compared to the overall distribution average due to higher margins in the related services.

Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa

Humira Abilify Seretide/Advair Lantus Enbrel CymbaltaRemicade Rituxan Neulasta

Percentage Share of Leading 10 Specialty Drugs in the US

by Revenue (2012)

U S $ B i l l i o n

The US Specialty Pharmaceutical Market (2008-2017E)



Table of Contents

1. Overview

1.1 Specialty Pharmaceuticals Vs Traditional Drugs1.2 Applications of Specialty Pharmaceuticals1.3 Specialty Pharmacy Services

1.3.1 Packaging and Delivery Services

1.3.2 Reimbursement Services1.3.3 Inbound and Outbound Clinical Support1.3.4 Compliance and Persistence Program

1.4 Specialty Product Distribution

1.4.1 Distribution Services

1.5 Specialty Pharma Manufacturer Services1.6 Value Proposition of Specialty Pharmacy

2. Market Size

2.1 Pharmaceutical Market

2.1.1 Global Analysis2.1.2 Regional Analysis2.2 The US Specialty Pharmaceutical Market-Market Value-Traditional Vs Specialty-Sales by Customers

-Sales by Dispensing Channels

2.2.1 The US Specialty Pharmaceutical Market byTherapeutic Area2.2.2 Specialty Pharmacy in the US

3. Market Dynamics

3.1 Growth Drivers

3.1.1 Accelerating US Aging Population

3.1.2 Increasing Life Expectancy Rate in the US

List of Charts & Tables

List of Charts

Flow of Products within the Specialty Pharmacy Channel SP Benefits Model Global Pharmaceutical Market (2003-2013E)Global Pharmaceutical Market – by Region (2012)Regional Percentage Share in Global Pharmaceutical Market (2012)The US Pharmaceutical Market (2008-2012)The US Traditional Pharmaceutical Market (2008-2012)The US Specialty Pharmaceutical Market (2008-2012)Percentage Share of Traditional and Specialty Pharmaceutical in the US(2012)Distributor Specialty Sales by Customer (2012)Specialty Market Share by Dispensing Channels (2012)Share of Constituents of Specialty Pharmaceutical Market (2012)Share of Therapeutics in Specialty Pharmacy Market (2012)The US Aging Population (2008-2012)

The US Life Expectancy Rate (2006-2013E)The US Healthcare Expenditure per Capita (2006-2012E)GNI of the US (2006-2012)Medicare Enrollments (2005-2014E)FDA Approval of New Molecule Entities (2003-2012)Growth in Specialty Drug v/s Non-Specialty Drug Spend

Specialty Drug Spending Trend (2012 & 2015E)Specialty Drug Patent to Generic Conversions (2013E-2020E)Biotechnology Drugs Currently in Development (2012)Percentage Share of Leading 10 Specialty Drugs in the US – by Revenue(2012)Specialty Mail Pharmacy Market Share (2012)Specialty Distributors Market Share (2012)Novo Nordisk Revenue Share by Business Segments (2013)Novo Nordisk Revenue Share by Business Segments (2013)Novo Nordisk Revenues & Net Income (2009-2013) Amgen’s Revenue Share by Business segment (2012)

Amgen’s Revenues and Net Income (2008-2012)



3.1.3 Rising Incidences of Complex Chronic Diseases3.1.4 Rising Pharmaceutical Sales3.1.5 Healthcare Reforms3.1.6 Escalating Healthcare Expenditure in the US3.1.7 Ameliorating Economic Conditions3.1.8 Patents Expiry of Bio Drugs

3.2 Trends and Developments

3.2.1 Increased Acceptance of Specialty Therapy

3.2.2 Mergers and Acquisitions3.2.3 Rising Medicare Enrollments3.2.4 Rising Number of New Molecular Entities3.2.5 Increased Spending on Specialty Drugs3.2.6 Shift from Specialty Drug Patents to Generic Conversion3.2.7 Novel Specialty Product in Pipeline

3.3 Challenges

3.3.1 Lack of Rigorous Clinical Trials

3.3.2 Rising Price Pressure3.3.3 Inadequate Innovations3.3.4 Inappropriate Use of Therapeutic Drugs

4. Competitive Landscape

4.1 Competition by Drugs4.2 Competition by Mail Pharmacy4.3 Competition by Specialty Distributor

5. Company Profiles

5.1 Novo Nordisk

5.1.1 Business Overview5.1.2 Financial Overview5.1.3 Business Strategies-Focus on Product Innovation-Establishing Presence in Obesity & Inflammation Treatments

5.2 Amgen Inc.

5.2.1 Business Overview5.2.2 Financial Overview

Pfizer’s Revenue Share by Business Segments (2013) Pfizer’s Revenues &

Net Income (2009-2013)Roche’s Revenue by Business Segments (2013) Roche Holding’s Revenue and Net Income (2009-2013)Johnson & Johnson’s Revenue Share by Business Segments (2013) Johnson & Johnson’s Revenues and Net Income (2009-2013)Eli Lilly’s Revenue and Net Income (2009-2013)

The US Specialty Pharmaceutical Market (2008-2017E)



5.2.3 Business Strategies-Business Expansion through Acquisitions-Advancements in Product Pipeline

5.3 Pfizer Inc.

5.3.1 Business Overview5.3.2 Financial Overview5.3.3 Business Strategies-Focus on Novel Product Development

-Growth through Strategic Acquisitions

5.4 Roche Holdings AG

5.4.1 Business Overview5.4.2 Financial Overview5.4.3 Business Strategies-Ceaseless Focus on R&D-Expansion through Strategic Collaboration

5.5 Johnson & Johnson

5.5.1 Business Overview5.5.2 Financial Overview5.5.3 Business Strategies-Novel Product Launch-Growth through Acquisitions

5.6 Eli Lilly and Company

5.6.1 Business Overview

5.6.2 Financial Overview5.6.3 Business Strategies-Focus on Novel Molecule Development-Expansion through Strategic Acquisitions

6. Market Outlook

6.1 Market Forecast6.2 Forecast Methodology

6.2.1 Dependent and Independent Variables6.2.2 Correlation Analysis6.2.3 Regression Analysis

List of Tables

Specialty Pharmaceuticals - Key Application Areas

Specialty Pharmacy v/s Specialty Distributors

Key Players Providing Manufacturer Services

The US Specialty Pharmaceutical Market Constituents (2012)Specialty Pharmacy Market – by Value (2011 & 2012)Expiry of Bio Drugs’ Patents by Company (2013-2019)

Comparison of Traditional Therapy and Specialty Therapy Specialty Pharmaceutical M&A (2007-2013)Larger Specialty Distribution Transactions (2005-2012)Projected Specialty Generic Launches (2013-2015)Specialty Drugs under Development Selected Product Launches (2012-2016)Leading 10 Specialty Drugs in the US (2012)Dependent & Independent Variables (2008 –2012)Correlation Matrix

Model Summary – Coefficient of Determination

Regression Coefficients Outpu



Koncept Analytics

CS-36, Second Floor, Ansal Plaza

Vaishali, Ghaziabad,

U.P. – 201010

T. +91-120-4130959

C: +91-9811715635

[email protected]

Contact Us:

www.konceptanalytics.com

Vikas Gupta

BD Manager

These are abridged and sanitized sample pages from the comprehensive report on the The US Specialty Pharmaceutical

Market Report . To know more about this report or for any customized research requirement, please contact the following:

View Report Details








The US Specialty Pharmaceutical Market Report: 2013 Edition - New Report by Koncept Analytics

Documents

Transcript of The US Specialty Pharmaceutical Market Report: 2013 Edition - New Report by Koncept Analytics